Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roy Gerth van Wijk is active.

Publication


Featured researches published by Roy Gerth van Wijk.


World Allergy Organization Journal | 2009

Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009

G. Walter Canonica; Jean Bousquet; Thomas Casale; Richard F. Lockey; Carlos E. Baena-Cagnani; Ruby Pawankar; Paul C. Potter; Philippe Jean Bousquet; Linda Cox; Stephen R Durham; Harold S. Nelson; Giovanni Passalacqua; Dermot Ryan; Jan Brozek; Enrico Compalati; Ronald Dahl; Luís Delgado; Roy Gerth van Wijk; Richard G. Gower; Dennis K. Ledford; Nelson Augusto Rosário Filho; E. Valovirta; O. M. Yusuf; Torsten Zuberbier; Wahiduzzaman Akhanda; Raúl Lázaro Castro Almarales; Ignacio J. Ansotegui; Floriano Bonifazi; Jan Ceuppens; Tomás Chivato

Chair: G. Walter Canonica Co-Chairs Jean Bousquet, Thomas Casale, Richard F. Lockey, Carlos E. Baena-Cagnani, Ruby Pawankar, Paul C. Potter Authors Philippe J. Bousquet, Linda S. Cox, Stephen R. Durham, Harold S. Nelson, Giovanni Passalacqua, Dermot P. Ryan, Jan L. Brozek, Enrico Compalati, Ronald Dahl, Luis Delgado, Roy Gerth van Wijk, Richard G. Gower, Dennis K. Ledford, Nelson Rosario Filho, Erkka J. Valovirta, Osman M. Yusuf, Torsten Zuberbier Co-Authors Wahiduzzaman Akhanda, Raul Castro Almarales, Ignacio Ansotegui, Floriano Bonifazi, Jan Ceuppens, Tomás Chivato, Darina Dimova, Diana Dumitrascu, Luigi Fontana, Constance H. Katelaris, Ranbir Kaulsay, Piotr Kuna, Désirée Larenas-Linnemann, Manolis Manoussakis, Kristof Nekam, Carlos Nunes, Robyn O’Hehir, José M. Olaguibel, Nerin Bahceciler Onder, Jung Won Park, Alfred Priftanji, Robert Puy, Luis Sarmiento, Glenis Scadding, Peter Schmid-Grendelmeier, Ester Seberova, Revaz Sepiashvili, Dírceu Solé, Alkis Togias, Carlo Tomino, Elina Toskala, Hugo Van Beever, Stefan Vieths


Allergy | 2009

Sub-lingual immunotherapy: World allergy organization position paper 2009

G. Walter Canonica; Jean Bousquet; Thomas B. Casale; Richard F. Lockey; Carlos E. Baena-Cagnani; Ruby Pawankar; Paul C. Potter; Philippe Jean Bousquet; Linda Cox; Stephen R. Durham; Harold S. Nelson; Giovanni Passalacqua; Dermot Ryan; Jan Brozek; Enrico Compalati; Ronald Dahl; Luís Delgado; Roy Gerth van Wijk; Richard G. Gower; Dennis K. Ledford; Nelson Augusto Rosário Filho; Erkka Valovirta; O. M. Yusuf; Torsten Zuberbier; Wahiduzzaman Akhanda; Raúl Lázaro Castro Almarales; Ignacio J. Ansotegui; Floriano Bonifazi; Jan Ceuppens; Tomás Chivato

Co-Authors: Wahiduzzaman Akhanda, Raul Castro Almarales, Ignacio Ansotegui, Floriano Bonifazi, Jan Ceuppens, Tomás Chivato, Darina Dimova, Diana Dumitrascu, Luigi Fontana, Constance HKatelaris, Ranbir Kaulsay, Piotr Kuna, Dèsirée Larenas-Linnemann, Manolis Manoussakis, Kristof Nekam, Carlos Nunes, Robyn O’Hehir, José M Olaguibel, Nerin Bahceciler Onder, JungWon Park, Alfred Priftanji, Robert Puy, Luis Sarmiento, Glenis Scadding, Peter Schmid-Grendelmeier, Ester Seberova, Revaz Sepiashvili, Dirceu Solé, Alkis Togias, Carlo Tomino, Elina Toskala, Hugo Van Beever, Stefan Vieths*


The Journal of Allergy and Clinical Immunology | 1996

The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis

Tineke de Graafin't Veld; Susanne Koenders; Ingrid M. Garrelds; Roy Gerth van Wijk

BACKGROUND A clinical test that could inform the clinician about the severity of a patients nasal symptoms and health-related quality of life (QOL) would be very useful. OBJECTIVE We attempted to determine whether, in patients with perennial allergic rhinitis, nasal challenge with histamine could be used to estimate daily symptoms and QOL. METHODS Forty-eight patients with perennial allergic rhinitis were challenged with histamine to determine nasal hyperreactivity. Nasal response was monitored by the number of sneezes, the amount of secretion, and a symptom score. Daily nasal symptoms were recorded during the 2 preceding weeks. Patients also completed a rhinitis QOL questionnaire. RESULTS Responsiveness to histamine and total daily nasal symptoms were moderately correlated (r = 0.51, p = 0.001). Comparison of total daily nasal symptoms with the overall QOL score showed a moderate correlation (r = 0.59, p < 0.001). Nasal response to histamine and overall QOL score were also correlated (r = 0.43, p = 0.002). However, overall QOL and daily nasal symptoms could be predicted by wide 95% confidence intervals only for each decade of nasal responsiveness to histamine (expressed as a composite symptom score). CONCLUSION In patients with perennial allergic rhinitis nasal hyperreactivity as determined by histamine challenge, QOL, and daily nasal symptoms are moderately correlated. Therefore nasal histamine challenge can be used as a tool for estimating the severity of daily nasal symptoms and QOL, although it cannot predict nasal symptoms and QOL very accurately.


Pediatric Allergy and Immunology | 2008

Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review

Esther Röder; Marjolein Y. Berger; Hans de Groot; Roy Gerth van Wijk

Allergen‐specific immunotherapy is one of the cornerstones of allergic rhinoconjunctivitis treatment. Since the development of non‐invasive administration forms with better safety profiles, there is an increasing tendency to prescribe immunotherapy in youngsters. However, no overview is available on the efficacy of immunotherapy in all its different administration forms in youngsters. Therefore, we systematically reviewed randomized controlled trials (RCTs) to evaluate the effect of immunotherapy with inhalant allergens on symptoms and medication use in children and adolescents with allergic rhinoconjunctivitis. Medline, EMBASE, the Cochrane Controlled Clinical Trials Register and reference lists of recent reviews and published trials were searched. RCTs including youngsters aged 0–18 yr with allergic rhinoconjunctivitis and comparing immunotherapy with placebo, symptomatic treatment or a different administration form of immunotherapy were included. Primary outcome measures were rhinoconjunctivitis symptom and/or medication scores. Methodological quality was assessed using the validated Delphi list. A method of best evidence synthesis, a rating system with levels of evidence based on the overall quality and the outcome of the trials, was used to assess efficacy. Six subcutaneous (SCIT), four nasal (LNIT), seven oral (OIT) and 11 sublingual (SLIT) immunotherapy trials, comprising 1619 youngsters, were included. Only 39% of the trials were of high methodological quality. For the SCIT and OIT subgroups the level of evidence for efficacy was conflicting. Moderate evidence of effect was found for LNIT. Analysis of the SLIT subgroup showed no evidence of effect. The evidence for the perennial and seasonal allergen trials within the subgroups varied from moderate evidence of effect to no evidence of effect. In conclusion, there is at present insufficient evidence that immunotherapy in any administration form has a positive effect on symptoms and/or medication use in children and adolescents with allergic rhinoconjunctivitis.


Allergy | 2002

Prevalence of sensitization to the predatory mite Amblyseius cucumeris as a new occupational allergen in horticulture

C. Giséle; M. Groenewoud; C. De Graaf In 'T Veld; A. Van Oorschot-van Nes; Nicolette W. de Jong; A. M. Vermeulen; Albert W. Van Toorenenbergen; Alex Burdorf; Hans de Groot; Roy Gerth van Wijk

Background: Protection against thrips, a common pest in bell pepper horticulture is effectively possible without pesticides by using the commercially available predatory mite Amblyzeius cucumeris (Ac). The prevalence of sensitization to Ac among exposed greenhouse employees and its clinical relevance was studied.


Allergy | 2007

Nasal nitric oxide : longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis

J. D. Boot; Marieke de Kam; Mary Ann Mascelli; Barry Miller; Roy Gerth van Wijk; Hans de Groot; Adam F. Cohen; Zuzana Diamant

Background:  Exhaled nitric oxide (eNO) is a validated noninvasive marker of airway inflammation in asthma. In patients with allergic rhinitis (AR), increased levels of nasal nitric oxide (nNO) have also been measured. However, the applicability of nNO as a marker of upper airway inflammation awaits validation.


Contact Dermatitis | 1998

Prevalence of natural rubber latex allergy (Type I and Type IV) in laboratory workers in The Netherlands

Hans de Groot; Nicolette W. de Jong; Ellen Duijster; Roy Gerth van Wijk; A. M. Vermeulen; Albert W. Van Toorenenbergen; Lidy Geursen; Theo van Joost

The objective of the study was to study the prevalence of Type IV and Type I allergy to natural rubber latex (NRL) in a population at risk in the Netherlands. Laboratory workers regularly using gloves were invited to complete a questionnaire and to be tested. We performed patch tests with standard contact allergens, rubber additives, glove powder and pieces of 4 gloves; prick tests with inhalant allergens, glove extracts, glove powder and fruit extracts; and RASTs. Glove‐related hand dermatitis was reported in 36.9% of the individuals interviewed. A positive patch test result for rubber additives was seen in only 6.6%. Glove‐related urticaria, rhinoconjunctivitis and/or asthma were reported in 24.6% of all cases. Confirmation of an IgE‐mediated reaction was achieved in 8.3% by prick test with glove extracts and 5.0% by RAST No reaction to glove powder was noticed in patch testing or in prick testing. A high prevalence rate of glove‐related symptoms and NRL Type I allergy was found in laboratory workers exposed to rubber gloves. Surprisingly, there was no co‐existence of Type I and Type IV allergy in this population.


Journal of Agricultural and Food Chemistry | 2016

Purification and Characterization of Anacardium occidentale (Cashew) Allergens Ana o 1, Ana o 2, and Ana o 3.

Marit Reitsma; Shanna Bastiaan-Net; Stefano Sforza; Johanna P.M. van der Valk; Roy Gerth van Wijk; H.F.J. Savelkoul; Nicolette W. de Jong; Harry J. Wichers

In this study a fast and simple purification procedure for the three known allergens from cashew (7S globulin Ana o 1, 11S globulin Ana o 2, and 2S albumin Ana o 3) is described. The purified allergens are characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Western blot, glycoprotein stain, and protein identification. The purified proteins still bind IgE, and this IgE binding varied between different pools of patient serum. Ana o 1 was found to be a glycoprotein. Ana o 3 has been studied more in detail to identify both the small and large subunits, both displaying microheterogeneity, and epitope mapping of Ana o 3 has been performed.


Primary Care Respiratory Journal | 2013

Sensitisation patterns and association with age, gender, and clinical symptoms in children with allergic rhinitis in primary care: a cross-sectional study.

Cindy M. A. de Bot; Esther Röder; David H. J. Pols; Patrick J. E. Bindels; Roy Gerth van Wijk; Johannes C. van der Wouden; Heleen Moed

Background: Polysensitisation is a frequent phenomenon in patients with allergic rhinitis. However, few studies have investigated the characteristics of polysensitised children, especially in primary care. Objectives: This analysis describes the patterns of sensitisation to common allergens and the association with age, gender, and clinical symptoms in children in primary care diagnosed with allergic rhinitis. Methods: Cross-sectional data from two randomised double-blind placebo-controlled studies were used to select children aged 6–18 years (n=784) with a doctors diagnosis of allergic rhinitis or use of relevant medication for allergic rhinitis in primary care. They were assessed for age, gender, specific IgE (type and number of sensitisations), nasal and eye symptom scores. Results: In 699 of the 784 children (89%) with a doctors diagnosis or relevant medication use, a positive IgE test for one or more allergens was found. Polysensitisation (≥2 sensitisations) was found in 69% of all children. Sensitisation was more common in children aged 9–13 than in younger children aged 5–8 years (p=0.03). Monosensitisation and polysensitisation were not significantly different in girls and boys. The severity of clinical symptoms did not differ between polysensitised and monosensitised children, but symptoms were significantly lower in non-sensitised children. Conclusions: Polysensitisation to multiple allergens occurs frequently in children with allergic rhinitis in general practice. Overall, clinical symptoms are equally severe in polysensitised and monosensitised children. Treatment decisions for allergic rhinitis should be made on the basis of a clinical history and allergy testing.


Mediators of Inflammation | 2013

Evaluation of Clinical and Immunological Responses: A 2-Year Follow-Up Study in Children with Allergic Rhinitis due to House Dust Mite

Heleen Moed; Roy Gerth van Wijk; Rudi W. Hendriks; J.C. van der Wouden

Background. Allergic rhinitis is a disease with polarization towards Th2 and a defect of regulatory T cells. Immunological changes have been reported after immunotherapy treatment. However, there is not much known about the natural course of allergic rhinitis with respect to clinical manifestation and the relation with immunological responses. Objective. To evaluate clinical symptoms of allergic rhinitis, in relation to in vivo allergen-specific skin responses and in vitro allergen-specific effector and regulatory T cells determined at baseline and after two years. Methods. From a large trial, 59 children were randomly selected. The following variables were compared: clinical symptoms, allergen skin tests, specific IgE, T-cell proliferation, IL-5, IL-13, IFN-gamma, IL-10, TGF-beta, CD4+CD25hi cells, and Foxp3 expression. Results. Allergic symptoms had decreased after two years. Whereas skin test reactions correlated between years 0 and 2, there was no change in the size of the reaction. Also, proinflammatory reactions did not change after two years, with a positive correlation between years 0 and 2. No relevant changes were observed with respect to regulatory cells. Conclusion. Whereas, comparable to immunotherapy, allergic complaints decrease, the immunological changes of specific T-cell activity (both effector cells and regulator cells) which are observed after immunotherapy, do not change.

Collaboration


Dive into the Roy Gerth van Wijk's collaboration.

Top Co-Authors

Avatar

Hans de Groot

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Nicolette W. de Jong

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Esther Röder

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Carlos E. Baena-Cagnani

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sergio Bonini

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Linda Cox

Nova Southeastern University

View shared research outputs
Researchain Logo
Decentralizing Knowledge